Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active …

C Loo, N Glozier, D Barton, BT Baune… - The British Journal of …, 2023 - cambridge.org
BackgroundPrior trials suggest that intravenous racemic ketamine is a highly effective for
treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed …
被引用次数：19 相关文章

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active …

C Loo, N Glozier, D Barton, BT Baune… - The British Journal …, 2023 - research.monash.edu
Background Prior trials suggest that intravenous racemic ketamine is a highly effective for
treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed …

Efficacy and Safety of Repeated Subcutaneous Ketamine Injections for Treatment Resistant Depression-The KADS Study: A Randomised, Double-Blind, Comparator …

CK Loo, N Glozier, D Barton, BT Baune… - The British Journal …, 2023 - research.bond.edu.au
Background Prior trials suggest that intravenous racemic ketamine is a highly effective for
treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed …
[HTML] nih.gov

[HTML][HTML] Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double …

C Loo, N Glozier, D Barton, BT Baune… - The British Journal of …, 2023 - ncbi.nlm.nih.gov
Background Prior trials suggest that intravenous racemic ketamine is a highly effective for
treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed …

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active …

C Loo, N Glozier, D Barton… - The British journal …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Prior trials suggest that intravenous racemic ketamine is a highly effective for
treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed …

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active …

C Loo, N Glozier, D Barton, BT Baune… - The British Journal of …, 2023 - cambridge.org
BackgroundPrior trials suggest that intravenous racemic ketamine is a highly effective for
treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed …

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active …

C Loo, N Glozier, D Barton, BT Baune, NT Mills… - 2023 - dro.deakin.edu.au
Background Prior trials suggest that intravenous racemic ketamine is a highly effective for
treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed …

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active …

C Loo, N Glozier, D Barton, B Baune… - The British Journal of …, 2023 - europepmc.org
Background Prior trials suggest that intravenous racemic ketamine is a highly effective for
treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed …

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active …

C Loo, N Glozier, D Barton… - British Journal …, 2023 - research-repository.uwa.edu.au
Background Prior trials suggest that intravenous racemic ketamine is a highly effective for
treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed …

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active …

C Loo, N Glozier, D Barton, BT Baune, NT Mills… - 2023 - dro.deakin.edu.au
Background Prior trials suggest that intravenous racemic ketamine is a highly effective for
treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed …